Total population | Biologic naive | Biologic experienced | |||||||
---|---|---|---|---|---|---|---|---|---|
CCP+ | CCP+ | CCP+ | CCP+ | CCP+ | CCP+ | ||||
abatacept initiators n=330 | TNFi initiators | abatacept initiators | TNFi initiators | abatacept initiators | TNFi initiators | ||||
n=330 | n=330 | n=97 | n=97 | n=233 | n=233 | ||||
Primary outcome: | Mean (±SE) | Mean (±SE) | p value* | Mean (±SE) | Mean (±SE) | p value* | Mean (±SE) | Mean (±SE) | p value* |
Change in CDAI | –9.9 (±0.8) | –8.5 (±0.8) | 0.24 | –9.8 (±1.4) | –12.3 (±1.4) | 0.19 | –9.9 (±1.0) | –7.0 (±1.0) | 0.033 |
Secondary outcomes: | Response rate (%) | Response rate (%) | p value† | Response rate (%) | Response rate (%) | p value† | Response rate (%) | Response rate (%) | p value† |
LDA | 41.3 | 39.7 | 0.69 | 50.0 | 57.0 | 0.36 | 37.6 | 32.1 | 0.26 |
Remission | 15.5 | 14.8 | 0.83 | 19.6 | 21.6 | 0.72 | 13.7 | 12.0 | 0.58 |
mACR20 | 36.4 | 36.4 | >0.99 | 40.2 | 45.4 | 0.47 | 34.8 | 32.6 | 0.62 |
mACR50 | 24.8 | 21.5 | 0.31 | 26.8 7 37.1 | 0.12 | 24.0 | 15.0 | 0.014 | |
mACR70 | 13.6 | 10.6 | 0.23 | 17.5 | 19.6 | 0.71 | 12.0 | 6.9 | 0.057 |
*t-test, †chi-square test.